Internal Medicine

Liver Function Tests (LFTs) Interpretation

The Liver: Anatomy of a Metabolic Powerhouse

Amos Asamoah
October 2025
10 min read
Other Topics

Liver Function Tests (LFTs) represent a crucial panel of blood tests that assess the health and function of one of the body's most vital organs: the liver. Often misunderstood as simply "liver tests," LFTs actually evaluate three distinct aspects: hepatocellular injury, cholestasis (bile flow obstruction), and synthetic function. Think of the liver as a sophisticated chemical processing plant; LFTs help us determine if the plant is damaged, if its drainage pipes are blocked, or if it's failing to produce essential products. Proper interpretation requires understanding what each test measures and recognizing characteristic patterns that point to specific liver disorders.

๐Ÿญ The Liver: Anatomy of a Metabolic Powerhouse

To interpret LFTs effectively, one must first understand the liver's complex architecture and functions. The liver performs over 500 vital functions, making it the body's primary metabolic and detoxification center:

๐Ÿงฌ Functional Anatomy & Zonation

  • Hepatocytes: The main functional cells (80% of liver mass)
  • Lobule Architecture: Hexagonal units with central veins and portal triads
  • Zones 1-3: Periportal (zone 1), midzonal (zone 2), centrilobular (zone 3)
  • Zone-Specific Vulnerability:
    • Zone 1: Rich in oxygen, vulnerable to viral hepatitis
    • Zone 3: Low oxygen, vulnerable to ischemic injury, alcohol, acetaminophen
  • Biliary Tree: Canaliculi โ†’ bile ductules โ†’ hepatic ducts โ†’ common bile duct
  • Dual Blood Supply: Portal vein (75%, nutrient-rich) and hepatic artery (25%, oxygen-rich)
  • Key Point: Different injuries affect different zones, producing distinct LFT patterns

โš™๏ธ Major Liver Functions

  • Metabolic Functions:
    • Carbohydrate metabolism: Gluconeogenesis, glycogen storage
    • Protein metabolism: Synthesis (albumin, clotting factors), degradation
    • Lipid metabolism: Cholesterol synthesis, lipoprotein production
  • Detoxification & Excretion:
    • Phase I: Oxidation/reduction (CYP450 enzymes)
    • Phase II: Conjugation (glucuronidation, sulfation)
    • Bile production: 500-1000 mL/day
  • Storage Functions:
    • Glycogen, vitamins (A, D, E, K, B12)
    • Iron, copper
  • Immunological Functions:
    • Kupffer cells: Hepatic macrophages
    • Removal of bacteria/toxins from portal blood
  • Key Point: Different LFTs assess different functional compartments

๐Ÿ”ฌ The LFT Panel: What's Actually Measured

  • Hepatocellular Injury Markers:
    • ALT (Alanine Aminotransferase)
    • AST (Aspartate Aminotransferase)
  • Cholestasis/Biliary Markers:
    • ALP (Alkaline Phosphatase)
    • GGT (Gamma-Glutamyl Transferase)
    • Bilirubin (total, direct, indirect)
  • Synthetic Function Markers:
    • Albumin
    • Prothrombin Time (PT)/INR
  • Other Important Tests:
    • Total protein
    • LDH (non-specific)
    • Ammonia (in hepatic encephalopathy)
  • Key Point: No single test assesses "liver function" comprehensively

๐ŸŽฏ The Three-Compartment Model

  • Compartment 1: Hepatocytes
    • Assessed by: ALT, AST
    • Elevation indicates: Cell injury/necrosis
    • Pattern: Hepatocellular pattern
  • Compartment 2: Biliary System
    • Assessed by: ALP, GGT, bilirubin
    • Elevation indicates: Bile flow obstruction
    • Pattern: Cholestatic pattern
  • Compartment 3: Synthetic Capacity
    • Assessed by: Albumin, PT/INR
    • Abnormality indicates: Functional impairment
    • Pattern: Synthetic dysfunction
  • Clinical Correlation:
    • Acute hepatitis: โ†‘โ†‘ ALT/AST, normal synthetic function
    • Cirrhosis: Mild โ†‘ ALT/AST, โ†“ albumin, โ†‘ PT
    • Biliary obstruction: โ†‘โ†‘ ALP/GGT, โ†‘ bilirubin
  • Key Point: Pattern recognition is more important than isolated values
๐ŸŽฏ Clinical Memory Aid: Remember the three LFT patterns:
  • Hepatocellular: ALT/AST โ†‘โ†‘ (cell injury)
  • Cholestatic: ALP/GGT โ†‘โ†‘ (bile flow problem)
  • Synthetic Dysfunction: Albumin โ†“, PT โ†‘ (factory failure)

๐Ÿ”ฌ Hepatocellular Injury Markers: ALT & AST

Aminotransferases (transaminases) are enzymes released from damaged hepatocytes. Their patterns and ratios provide crucial diagnostic information about the type and severity of liver injury:

๐Ÿ”„ ALT (Alanine Aminotransferase)

  • Full Name: Alanine Aminotransferase (formerly SGPT)
  • Cellular Location: Primarily cytoplasmic (90%), mitochondrial (10%)
  • Liver Specificity: Highly liver-specific (more than AST)
  • Normal Range: 7-56 U/L (varies by lab)
  • Half-life: Approximately 47 hours (longer than AST)
  • Clinical Significance:
    • Mild Elevation (1-2x ULN): NAFLD, chronic hepatitis, medications
    • Moderate Elevation (2-5x ULN): Viral hepatitis, alcohol, autoimmune hepatitis
    • Marked Elevation (>10x ULN): Acute viral hepatitis, ischemic hepatitis, toxin/drug injury
    • Extreme Elevation (>1000 U/L): Acetaminophen toxicity, ischemic hepatitis, acute viral hepatitis
  • Key Point: The most specific marker for hepatocellular injury
  • Clinical Pearl: In alcoholic hepatitis, ALT often <300 U/L ("AST:ALT >2:1 rule")

๐Ÿ”„ AST (Aspartate Aminotransferase)

  • Full Name: Aspartate Aminotransferase (formerly SGOT)
  • Cellular Location: Cytoplasmic (20%), mitochondrial (80%)
  • Tissue Distribution: Liver, heart, skeletal muscle, kidney, brain, RBCs
  • Normal Range: 10-40 U/L (varies by lab)
  • Half-life: Approximately 17 hours (shorter than ALT)
  • Clinical Significance:
    • Liver Sources: Hepatocellular injury (less specific than ALT)
    • Non-liver Sources:
      • Cardiac: MI (peaks 24-48h, returns to normal in 4-6 days)
      • Muscle: Rhabdomyolysis, strenuous exercise
      • Hemolysis: False elevation from RBC breakdown
      • Other: Renal infarction, pancreatitis, shock
  • The AST:ALT Ratio (DeRitis Ratio):
    • >2:1: Suggests alcoholic liver disease (sensitivity 70-80%)
    • <1: Typical of non-alcoholic liver disease, viral hepatitis
    • >3:1: Suggests alcoholic hepatitis with cirrhosis
    • ~1:1: Non-specific, seen in various conditions
  • Key Point: Less liver-specific than ALT; always correlate with clinical context
  • Clinical Pearl: In acute MI, AST rises and falls earlier than CK-MB or troponin
Condition ALT Pattern AST Pattern AST:ALT Ratio Typical Peak Values
Acute Viral Hepatitis โ†‘โ†‘โ†‘ (500-5000) โ†‘โ†‘โ†‘ (slightly lower) <1 Week 2-3 of illness
Alcoholic Hepatitis โ†‘ (usually <300) โ†‘โ†‘ (often >150) >2:1 During heavy drinking
Acetaminophen Toxicity โ†‘โ†‘โ†‘โ†‘ (>1000) โ†‘โ†‘โ†‘โ†‘ (similar) ~1:1 24-72h post-ingestion
NAFLD/NASH โ†‘ (mild-mod) โ†‘ (mild, often <1 Chronic elevation
Autoimmune Hepatitis โ†‘โ†‘ (200-1000) โ†‘โ†‘ (similar) ~1:1 During flare
Ischemic Hepatitis โ†‘โ†‘โ†‘โ†‘ (>1000) โ†‘โ†‘โ†‘โ†‘ (similar) ~1:1 24-48h post-event
๐Ÿ”ฌ Clinical Insight: The magnitude of transaminase elevation does NOT necessarily correlate with disease severity or prognosis. A patient with cirrhosis may have only mildly elevated ALT/AST, while someone with acute viral hepatitis may have levels in the thousands but recover completely. However, in acetaminophen toxicity, the degree of elevation DOES correlate with prognosis (King's College criteria: PT >100s or pH <7.3 with ALT >1000 indicates need for transplant).

๐ŸŸก Cholestatic Markers: ALP, GGT & Bilirubin

Cholestasis refers to impaired bile flow, either within hepatocytes (intrahepatic) or in bile ducts (extrahepatic). These markers help localize the site of obstruction and assess its severity:

ALP (Alkaline Phosphatase)

  • Full Name: Alkaline Phosphatase
  • Sources: Liver (canaliculi), bone (osteoblasts), placenta, intestine
  • Isoenzymes: Liver (heat-stable), bone (heat-labile), placental, intestinal
  • Normal Range: 44-147 U/L (higher in children, pregnant women)
  • Mechanism of Elevation:
    • Increased synthesis by hepatocytes in response to bile duct obstruction
    • Release from damaged biliary epithelial cells
  • Liver-Specific Elevation:
    • Concomitant โ†‘ in GGT confirms hepatic origin
    • Isoenzyme electrophoresis if needed
  • Causes of Elevated ALP:
    • Hepatobiliary: Bile duct obstruction (stones, stricture, tumor), PBC, PSC, drug-induced cholestasis
    • Bone: Paget's disease, bone metastases, healing fractures, osteomalacia
    • Other: Pregnancy (placental), intestinal ischemia, sepsis
  • Clinical Pearl: ALP elevation typically exceeds transaminase elevation in cholestatic disorders (>2x ULN ALP vs <5x ULN AST/ALT)

GGT (Gamma-Glutamyl Transferase)

  • Full Name: Gamma-Glutamyl Transferase (or Gamma-Glutamyl Transpeptidase)
  • Specificity: Highly sensitive for hepatobiliary disease but not specific
  • Normal Range: 9-58 U/L (men), 9-36 U/L (women)
  • Clinical Uses:
    • Confirm hepatic origin of ALP: โ†‘ ALP + โ†‘ GGT = hepatic source
    • Alcohol consumption marker: Induced by ethanol (even without liver disease)
    • Drug-induced liver injury: Often elevated in cholestatic DILI
  • Limitations:
    • Elevated in many non-liver conditions: pancreatitis, MI, renal failure
    • Induced by many medications: anticonvulsants (phenytoin), NSAIDs, statins
    • Not useful as isolated screening test
  • GGT:ALP Ratio:
    • >2.5: Suggests alcohol-related liver disease
    • <2.5: Suggests other causes of cholestasis
  • Clinical Pearl: GGT has low specificity but high sensitivity for biliary disease

Bilirubin Metabolism & Measurement

  • Production: 250-300 mg/day from heme breakdown (80% from senescent RBCs)
  • Metabolism Steps:
    • Unconjugated (indirect): Water-insoluble, bound to albumin
    • Hepatic uptake: Transport into hepatocytes
    • Conjugation: With glucuronic acid โ†’ bilirubin diglucuronide
    • Excretion: Into bile โ†’ intestine โ†’ urobilinogen โ†’ stool/urine
  • Total Bilirubin: Normal <1.2 mg/dL (20 ฮผmol/L)
  • Direct (Conjugated) Bilirubin: Normal <0.3 mg/dL (5 ฮผmol/L)
  • Indirect (Unconjugated) Bilirubin: Calculated (Total - Direct)
  • Hyperbilirubinemia Patterns:
    • Unconjugated predominant (>80% indirect): Hemolysis, Gilbert's, Crigler-Najjar
    • Conjugated predominant (>50% direct): Hepatocellular disease, biliary obstruction
    • Mixed pattern: Many liver diseases
  • Clinical Pearl: Urine bilirubin detects only conjugated bilirubin (water-soluble)
Condition ALP GGT Bilirubin Pattern Typical Ratio (ALP:ALT)
Bile Duct Obstruction โ†‘โ†‘โ†‘ (3-10x) โ†‘โ†‘โ†‘ โ†‘ direct (>50%) >2:1
Primary Biliary Cholangitis (PBC) โ†‘โ†‘โ†‘ (3-10x) โ†‘โ†‘โ†‘ Variable, late โ†‘ >3:1
Drug-Induced Cholestasis โ†‘โ†‘ (2-5x) โ†‘โ†‘โ†‘ โ†‘ (mixed) >2:1
Infiltrative Liver Disease โ†‘โ†‘ (2-5x) โ†‘ (mild-mod) Usually normal >2:1
Alcoholic Liver Disease โ†‘ (mild-mod) โ†‘โ†‘โ†‘ (disproportionate) Variable Variable

๐Ÿ—๏ธ Synthetic Function Markers: Albumin & PT/INR

These tests assess the liver's capacity to produce essential proteins. Abnormalities indicate significant functional impairment and are markers of chronic liver disease severity:

๐Ÿงช Albumin

  • Production: Exclusively synthesized by hepatocytes (10-15g/day)
  • Half-life: Long (15-20 days) - reflects chronic, not acute, liver function
  • Functions:
    • Maintains oncotic pressure (75-80% of plasma oncotic pressure)
    • Transport protein (hormones, drugs, fatty acids, bilirubin)
    • Buffer capacity, antioxidant effects
  • Normal Range: 3.5-5.0 g/dL (35-50 g/L)
  • Causes of Low Albumin:
    • Decreased synthesis: Chronic liver disease, malnutrition, malabsorption
    • Increased loss: Nephrotic syndrome, protein-losing enteropathy, burns
    • Increased catabolism: Sepsis, trauma, cancer
    • Dilutional: Overhydration, pregnancy
  • Liver Disease Pattern:
    • Normal in acute hepatitis (short half-life)
    • Decreased in cirrhosis, chronic liver disease
    • Correlates with Child-Pugh and MELD scores
  • Clinical Pearl: Not specific for liver disease; always consider non-hepatic causes

โฑ๏ธ Prothrombin Time (PT) & INR

  • Measures: Extrinsic and common coagulation pathways (Factors I, II, V, VII, X)
  • Liver-synthesized factors: II, VII, IX, X (vitamin K-dependent), V, XI, XII, XIII, fibrinogen
  • Factor VII: Shortest half-life (4-6 hours) - earliest to decrease in liver failure
  • Normal PT: 11-13.5 seconds (varies by lab)
  • INR: International Normalized Ratio (corrects for reagent variability)
  • Causes of Prolonged PT:
    • Decreased synthesis: Liver failure, cirrhosis, acute liver failure
    • Vitamin K deficiency: Malabsorption, biliary obstruction, warfarin
    • Consumption: DIC, massive transfusion
    • Factor inhibitors
  • Vitamin K Challenge Test:
    • Give vitamin K 10mg SC/IV
    • PT corrects >30% in 24h: Vitamin K deficiency
    • PT doesn't correct: Impaired synthesis (liver failure)
  • Clinical Pearl: PT/INR is the best marker of acute liver function; elevated in both acute and chronic liver failure

๐Ÿ“Š Total Protein & Globulins

  • Total Protein: Albumin + globulins (normal: 6.0-8.3 g/dL)
  • Globulin Fraction: Calculated (Total protein - albumin)
  • Patterns in Liver Disease:
    • Chronic liver disease: โ†“ albumin, โ†‘ globulins (polyclonal gammopathy)
    • Cirrhosis: Albumin:globulin ratio reversed (normally >1)
    • Autoimmune hepatitis: Marked โ†‘ in gamma globulins
  • Serum Protein Electrophoresis (SPEP):
    • Albumin, alpha-1, alpha-2, beta, gamma fractions
    • Liver disease: Polyclonal increase in gamma region
    • Multiple myeloma: Monoclonal spike in gamma region
  • Clinical Significance:
    • Hypergammaglobulinemia in chronic liver disease due to portosystemic shunting (intestinal antigens bypass liver)
    • IgG โ†‘ in autoimmune hepatitis
    • IgM โ†‘ in primary biliary cholangitis
โš–๏ธ Child-Pugh Classification: Uses albumin, bilirubin, PT, ascites, encephalopathy
  • Class A (5-6 points): Good surgical risk, 1-year survival 100%
  • Class B (7-9 points): Moderate surgical risk, 1-year survival 80%
  • Class C (10-15 points): Poor surgical risk, 1-year survival 45%
MELD Score: Uses bilirubin, creatinine, INR - predicts 3-month mortality in cirrhosis, used for transplant prioritization

๐ŸŽฏ Pattern Recognition & Differential Diagnosis

Interpreting LFTs requires recognizing patterns that suggest specific disease processes. The R ratio helps classify liver injury patterns:

The R Ratio Classification

  • Formula: R = (ALT รท ULN) รท (ALP รท ULN)
  • Hepatocellular (R >5): ALT elevation predominates Examples: Viral hepatitis, autoimmune hepatitis, ischemic hepatitis, drug-induced hepatocellular injury (acetaminophen, statins).
  • Cholestatic (R <2): ALP elevation predominates Examples: Bile duct obstruction (stones, stricture, tumor), PBC, PSC, drug-induced cholestasis (amoxicillin-clavulanate, anabolic steroids).
  • Mixed (R = 2-5): Both ALT and ALP elevated Examples: Alcoholic hepatitis, infiltrative diseases (sarcoidosis, lymphoma, metastases), some drug reactions, sepsis.
  • Clinical Application:
    • Guides differential diagnosis
    • Helps select appropriate imaging (ultrasound for cholestatic, consider biopsy for hepatocellular)
    • Predicts drug-induced liver injury pattern

๐Ÿ” Common LFT Patterns & Their Causes

Isolated ALT/AST Elevation

  • Differential:
    • NAFLD/NASH (most common in developed countries)
    • Medications (statins, NSAIDs, antibiotics)
    • Alcohol (AST:ALT >2)
    • Muscle injury (AST > ALT, โ†‘ CK)
    • Hemolysis (AST > ALT, โ†“ haptoglobin, โ†‘ LDH)
    • Celiac disease (often overlooked)
  • Workup: Viral serologies, iron studies, ANA, ceruloplasmin (if <40 y), ultrasound
  • Key Point: Most common pattern in asymptomatic patients

Isolated ALP Elevation

  • Step 1: Check GGT to confirm hepatic origin
  • If GGT normal: Consider bone source (Paget's, metastases, hyperparathyroidism)
  • If GGT elevated:
    • Biliary obstruction (stones, tumor, stricture)
    • Infiltrative disease (sarcoidosis, metastases)
    • PBC/PSC (check AMA, pANCA)
    • Drug-induced (anabolic steroids, some antibiotics)
  • Workup: Ultrasound first, then MRCP/ERCP if obstruction suspected

Isolated Hyperbilirubinemia

  • Unconjugated (>80% indirect):
    • Hemolysis (โ†‘ reticulocytes, โ†“ haptoglobin, โ†‘ LDH)
    • Gilbert syndrome (mild, fasting/stress-induced, benign)
    • Crigler-Najjar (severe, presents in infancy)
  • Conjugated (>50% direct):
    • Dubin-Johnson syndrome (dark liver, urinary coproporphyrin I >80%)
    • Rotor syndrome (normal liver, urinary coproporphyrin I >65%)
    • Early/partial biliary obstruction
  • Workup: Fractionation crucial, hemolysis workup, genetic testing if chronic

Pan-LFT Elevation

  • Acute hepatitis pattern: ALT/AST >1000, ALP mildly โ†‘, bilirubin variable
    • Viral hepatitis (A, B, E)
    • Toxin/drug (acetaminophen, mushrooms)
    • Ischemic hepatitis (shock liver)
    • Autoimmune hepatitis flare
  • Chronic liver disease pattern: Mild-mod ALT/AST, ALP variable, โ†“ albumin, โ†‘ PT
    • Cirrhosis (any cause)
    • Severe alcoholic hepatitis
    • Advanced NAFLD/NASH
  • Workup: Depends on acuity and clinical presentation
Pattern Typical LFT Findings Common Causes First-line Investigation
Acute Hepatitis ALT >500, AST >500, mild โ†‘ ALP Viral hepatitis, drugs, ischemia Viral serologies, drug history, ultrasound
Alcoholic Liver Disease AST:ALT >2:1, โ†‘ GGT, mild-mod โ†‘ ALP Alcohol abuse History, AUDIT-C score, ultrasound
Biliary Obstruction ALP >3x ULN, โ†‘ GGT, โ†‘ direct bilirubin Gallstones, stricture, tumor Abdominal ultrasound (gold standard)
Chronic Hepatitis Mild-mod ALT/AST, normal synthetic function Chronic viral hepatitis, autoimmune, NAFLD Viral serologies, autoantibodies, elastography
Cirrhosis Mild ALT/AST, โ†“ albumin, โ†‘ PT, variable bilirubin All chronic liver diseases Elastography, platelet count, imaging
Infiltrative Disease โ†‘ ALP > ALT/AST, normal bilirubin early Metastases, sarcoidosis, amyloidosis CT/MRI, biopsy, search for primary

โš ๏ธ Critical Patterns & Emergencies

Certain LFT patterns indicate life-threatening conditions requiring immediate intervention:

๐Ÿšจ Critical LFT Patterns Requiring Immediate Action:
  • Acute Liver Failure (ALF): Jaundice + coagulopathy (INR >1.5) + encephalopathy Medical emergency. Causes: Acetaminophen (most common in US), viral hepatitis, drug reactions, Wilson disease, autoimmune hepatitis. Mortality 30-80% without transplant.
  • Severe Acetaminophen Toxicity: ALT >1000 + INR >2.0 (or pH <7.3) King's College criteria for transplant. N-acetylcysteine must be started within 8-10 hours for maximum benefit.
  • Ascending Cholangitis (Charcot's Triad): Fever + RUQ pain + jaundice + โ†‘ ALP/GGT/bilirubin Surgical emergency. Requires antibiotics + biliary drainage (ERCP/PTCD). Mortality up to 50% if untreated.
  • Budd-Chiari Syndrome: Rapid onset ascites + hepatomegaly + โ†‘ ALT/AST + โ†‘ ALP Hepatic venous outflow obstruction. Requires anticoagulation, possible TIPS or transplant.
  • Ischemic Hepatitis ("Shock Liver"): Sudden ALT/AST >1000 following hypotension Markers rise within 24h, peak at 48h, normalize in 7-10 days. Treat underlying cause.
  • Autoimmune Hepatitis Flare: ALT >500 + hypergammaglobulinemia Requires prompt steroids to prevent progression to cirrhosis.
๐Ÿ” Drug-Induced Liver Injury (DILI) Patterns:
  • Hepatocellular: ALT >3x ULN, R >5 (acetaminophen, INH, statins, NSAIDs)
  • Cholestatic: ALP >2x ULN, R <2 (amoxicillin-clavulanate, erythromycin, anabolic steroids)
  • Mixed: Both ALT and ALP elevated, R = 2-5 (phenytoin, sulfonamides)
  • Hy's Law: Drug-induced hepatocellular injury with jaundice carries 10-50% mortality
  • RUCAM Score: Validated causality assessment tool for DILI

๐Ÿ“ Abbreviations & Terminology

Essential abbreviations and terminology for LFT interpretation:

Abbreviation Full Name Definition/Context
LFTs Liver Function Tests Panel assessing injury, cholestasis, and synthetic function
ALT Alanine Aminotransferase Hepatocellular injury marker (formerly SGPT)
AST Aspartate Aminotransferase Hepatocellular injury marker, less specific (formerly SGOT)
ALP Alkaline Phosphatase Cholestasis marker, also from bone/placenta/intestine
GGT Gamma-Glutamyl Transferase Confirms hepatic origin of ALP, marker of alcohol use
PT Prothrombin Time Synthetic function marker, measures clotting factors
INR International Normalized Ratio Standardized PT measurement
ULN Upper Limit of Normal Reference range upper limit for each test
NAFLD Non-Alcoholic Fatty Liver Disease Fat accumulation without significant alcohol use
NASH Non-Alcoholic Steatohepatitis NAFLD with inflammation and hepatocyte injury
PBC Primary Biliary Cholangitis Autoimmune destruction of small bile ducts
PSC Primary Sclerosing Cholangitis Fibrosing inflammation of bile ducts
AMA Anti-Mitochondrial Antibodies Highly specific for PBC (>95%)
ANA Antinuclear Antibodies Positive in autoimmune hepatitis, other autoimmune diseases
ERCP Endoscopic Retrograde Cholangiopancreatography Procedure to visualize and treat biliary obstruction
MRCP Magnetic Resonance Cholangiopancreatography Non-invasive imaging of biliary tree
DILI Drug-Induced Liver Injury Liver damage caused by medications
MELD Model for End-Stage Liver Disease Score predicting 3-month mortality in cirrhosis
RUQ Right Upper Quadrant Anatomical location of liver and gallbladder
AMA Anti-Mitochondrial Antibody Specific for primary biliary cholangitis
SMA Smooth Muscle Antibody Positive in autoimmune hepatitis type 1
LKM Liver-Kidney Microsomal Antibody Positive in autoimmune hepatitis type 2
HCV Hepatitis C Virus Causes chronic hepatitis, cirrhosis, HCC
HBV Hepatitis B Virus Causes acute/chronic hepatitis, cirrhosis, HCC
HAV Hepatitis A Virus Causes acute hepatitis, never chronic
HCC Hepatocellular Carcinoma Primary liver cancer
TIPS Transjugular Intrahepatic Portosystemic Shunt Procedure for portal hypertension complications
NAC N-Acetylcysteine Antidote for acetaminophen toxicity
CK Creatine Kinase Muscle enzyme, distinguishes muscle vs liver source of AST
LDH Lactate Dehydrogenase Non-specific marker of cell injury, elevated in hemolysis
๐Ÿ“š Memory Aid: Key LFT patterns and ratios:
  • AST:ALT >2: Alcoholic liver disease (specificity ~90%)
  • ALT > ALP (R >5): Hepatocellular pattern (hepatitis)
  • ALP > ALT (R <2): Cholestatic pattern (obstruction)
  • GGT:ALP >2.5: Alcohol-related disease
  • Albumin <3.5 + INR >1.5: Significant synthetic dysfunction
  • Direct bilirubin >50%: Hepatobiliary disease
  • Indirect bilirubin >80%: Hemolysis or Gilbert's

๐ŸŽฏ Clinical Pearls & Interpretation Framework

Systematic approach to LFT interpretation:

  • Step 1: Classify the Pattern
    • Calculate R ratio: (ALT รท ULN) รท (ALP รท ULN)
    • Hepatocellular (R >5), Cholestatic (R <2), Mixed (R 2-5)
    • Check AST:ALT ratio for alcohol clues (>2 suggestive)
  • Step 2: Assess Synthetic Function
    • Albumin: Chronic function (half-life 20 days)
    • PT/INR: Acute function (Factor VII half-life 6 hours)
    • Vitamin K challenge if PT prolonged
  • Step 3: Evaluate Bilirubin
    • Fractionate: Conjugated vs unconjugated
    • Unconjugated >80%: Think hemolysis, Gilbert's
    • Conjugated >50%: Think hepatobiliary disease
  • Step 4: Consider Clinical Context
    • Acute vs chronic presentation
    • Symptoms: Jaundice, pruritus, pain, fever, weight loss
    • Risk factors: Alcohol, medications, toxins, travel, family history
    • Physical exam: Stigmata of chronic liver disease, hepatomegaly, ascites
  • Step 5: Order Targeted Investigations
    • Hepatocellular: Viral serologies, autoantibodies, iron/copper studies
    • Cholestatic: Ultrasound first, then MRCP/ERCP if obstruction
    • Synthetic dysfunction: Workup for cirrhosis causes
  • Step 6: Monitor & Reassess
    • Repeat LFTs to assess trend (improving vs worsening)
    • Monitor for complications (ascites, encephalopathy, bleeding)
    • Consider referral to hepatology for complex cases
๐Ÿ”ฌ LFT Interpretation Study Tips:
  • Master the three compartments: Injury (ALT/AST), cholestasis (ALP/GGT/bilirubin), synthetic (albumin/PT)
  • Learn the key ratios: AST:ALT, R ratio, GGT:ALP, bilirubin fractionation
  • Know pattern recognition: Hepatocellular vs cholestatic vs mixed
  • Understand half-lives: ALT (47h), AST (17h), albumin (20d), Factor VII (6h)
  • Recognize emergencies: Acute liver failure, ascending cholangitis, severe DILI
  • Know common causes: NAFLD (most common), alcohol, viral hepatitis, drugs
  • Use systematic approach: Pattern โ†’ synthetic function โ†’ bilirubin โ†’ context โ†’ investigations
  • Contextualize: Acute vs chronic, symptomatic vs asymptomatic, risk factors

๐Ÿงญ Key Principles of LFT Interpretation

Core concepts for effective LFT interpretation:

  • No Single "Liver Function Test": LFTs assess different aspects; synthesize the full picture
  • Pattern Over Isolated Values: The pattern of abnormalities is more important than any single value
  • Clinical Integration: Always interpret LFTs in clinical context (symptoms, signs, risk factors)
  • Acute vs Chronic Patterns: Differentiate based on acuity, synthetic function, and clinical presentation
  • Dynamic Monitoring: Trends over time often more informative than single measurements
  • Test Limitations: Know what each test measures (and doesn't measure)
  • Common Things Are Common: NAFLD is the most common cause of elevated LFTs in developed countries
  • Safety First: Recognize and act on emergency patterns immediately
  • Appropriate Investigation: Choose investigations based on pattern (ultrasound for cholestasis, serologies for hepatitis)
  • Multidisciplinary Approach: Involve hepatology, gastroenterology, surgery as needed

๐Ÿ Conclusion

Liver Function Tests represent a sophisticated diagnostic toolkit for assessing one of the body's most complex and vital organs. Far from being simple "liver tests," LFTs provide insights into three distinct aspects of hepatic health: hepatocellular integrity, biliary patency, and synthetic capacity. Mastery of LFT interpretation requires understanding the physiology behind each test, recognizing characteristic patterns, and integrating laboratory findings with clinical context.

The art of LFT interpretation lies in pattern recognition: distinguishing hepatocellular from cholestatic injury, acute from chronic processes, and benign from life-threatening conditions. Key ratios like AST:ALT, R ratio, and bilirubin fractionation provide valuable diagnostic clues. Synthetic function markers (albumin and PT/INR) offer prognostic information and guide management decisions in both acute and chronic liver disease.

In clinical practice, LFTs serve multiple roles: as screening tools in asymptomatic individuals, as diagnostic aids in symptomatic patients, as monitors of disease progression or treatment response, and as prognostic indicators in advanced liver disease. With the global rise of metabolic liver diseases like NAFLD, and the persistent challenges of viral hepatitis and alcohol-related liver disease, proficiency in LFT interpretation remains an essential skill for all clinicians. Remember: LFTs tell a story about liver health; learning to read that story accurately can guide interventions that prevent progression from injury to irreversible failure.

Liver Function Test interpretation combines biochemical knowledge with clinical wisdom โ€” recognizing patterns while remembering that laboratory values must always be interpreted in the context of the whole patient. The liver speaks through its enzymes and proteins; learning this language enables clinicians to diagnose, monitor, and treat liver disorders effectively.

โ† Previous Topic: Full Blood Count โ†’ Next Topic: Kidney Function Tests โ†’